Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1543 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Yingxue Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: IPSEN BIOSCIENCE INC, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Itraconazole, Rifampin, Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A Inducers. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study (NCT04537715) investigated itraconazole (strong cytochrome P450 [CYP] 3A inhibitor) and rifampin (strong CYP3A inducer) on tazemetostat pharmacokinetics. In Part 1, patients received tazemetostat 400 mg orally on Days 1, 15, and 36, and 400 mg twice daily on Days 3‐14 and Days 21‐35. Itraconazole 200 mg orally once daily was administered on Days 18‐38. In Part 2, patients received tazemetostat 800 mg orally once daily on Days 1, 15, and 24, and 800 mg twice daily on Days 3‐14 and Days 17‐23. Rifampin 600 mg orally once daily was administered on Days 17‐25. Twenty‐one patients in each part completed had plasma concentrations quantified for pharmacokinetic assessments. Itraconazole coadministration resulted in higher tazemetostat exposures after single doses (Day 21/Day 1) and steady state (Day 36/Day 15). Compared with tazemetostat alone, itraconazole increased mean maximum plasma concentration (C max ) and area under the concentration‐time curve from time 0 to 12 hours (AUC 0‐12h ) by 2.00‐ and 3.12‐fold, respectively, after single doses. Following twice‐daily dosing, itraconazole increased mean steady‐state C max and AUC 0‐12h by 1.86‐ and 2.47‐fold, respectively. Rifampin coadministration decreased tazemetostat steady‐state (C max ) and AUC 0‐12h by approximately 84% (Day 24/Day 15). Itraconazole increased tazemetostat exposure by 2‐3‐fold, and rifampin decreased tazemetostat exposure by 84%, indicating that coadministration of tazemetostat with strong CYP3A inhibitors or inducers should be avoided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IPSEN BIOSCIENCE INC, Cambridge, MA, USA.
- CareCeutics, LLC, Berwyn, PA, USA.
- Ipsen Innovation, Les Ulis, France.
- Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
Zitieren
APA
Chen, Y., Teng, R., Szanto, A., Kapopara, A., Bannerji, R., Ogier, J., & Mahalingam, D. (2025). Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1543
Vancouver
Chen Y, Teng R, Szanto A, Kapopara A, Bannerji R, Ogier J, et al. Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1543
BibTeX
@article{Chen2025,
author = {Chen, Yingxue and Teng, Renli and Szanto, Attila and Kapopara, Apoorva and Bannerji, Rajat and Ogier, Julien and Mahalingam, Devalingam},
title = {Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1543}
}
EUVIMED